Russian-German venture: Maxwell Biotech + High-Tech Grunderfonds
Maxwell Biotech and High-Tech Grunderfonds venture Funds will invest in biopharmaceuticals and medicine
The funds intend to develop a strategic partnership for investment activities in the biopharmaceutical and medical industries of Russia and Germany. Within the framework of the partnership, the foundations will join efforts to introduce innovations in the field of medicine, using the experience and resources of their countries.
The main areas of cooperation of the funds will be: identifying priority areas of the biotechnology industry of mutual interest, attracting leading specialists ("opinion leaders") and experts from Russia, Germany and other countries to conduct scientific and technical expertise. The partners will conduct a joint comprehensive assessment of new investment opportunities, co-investment of existing portfolio companies of both funds, as well as exchange information on the market situation, regulatory requirements and any information related to the development of biotechnological and pharmaceutical products in Russia and Germany.
Maxwell Biotech and HTGF are actively investing in biotech companies engaged in the development of innovative therapeutic and diagnostic drugs, medical equipment, as well as related products and technologies. The funds have already gained positive experience in implementing joint projects – in March 2012, Maxwell Biotech and HTGF announced the first such project, which resulted in investing in MYR GmbH, a portfolio company of HTGF, as well as in Hepatera LLC, a Russian biotechnology company, a resident of the Biomedical Cluster of Innovative the Skolkovo Center.
Bernd Gergen, Senior Investment Manager at High-Tech Grunderfonds: "Joining forces with the right people is a key success factor in creating and maintaining sustainable development of companies not only in the field of biotechnology, but also in the venture industry. That is why we are very pleased that Maxwell Biotech is joining our partners, and we are looking forward to new successful projects that will have a beneficial effect on the development of our portfolio companies, our organizations and our markets."
Dmitry Popov, Managing Partner of Maxwell Biotech Venture Fund: "We are very pleased with the development of our cooperation with HTGF, which is not limited to one transaction, and we are confident that the signing of this agreement will significantly expand the opportunities for our further cooperation. Given the successful experience, we hope to build a mutually beneficial and effective partnership, the results of which will have a beneficial effect on the development of the venture capital investment market and lead to the emergence of innovative products and technologies."
Portal "Eternal youth" http://vechnayamolodost.ru
05.04.2012